Gilead Sciences has announced the acquisition of Arcellx, a biotechnology company, for $7.8 billion. This strategic move aims to enhance Gilead's oncology portfolio and expand its capabilities in cell therapy.
Related articles
Press ReleaseMay 8, 2026
West Enclave Merger Corp. Announces the Separate Trading of its Ordinary Shares and Rights, Commencing May 13, 2026
May 8, 2026
Press ReleaseMay 8, 2026
Shreya Acquisition Group Announces Closing of $110 Million Initial Public Offering (Including Partial Exercise of Over-Allotment Option)
May 8, 2026
Press ReleaseMay 8, 2026
Con Edison Announces $2 Billion At-The-Market (ATM) Equity Offering Program
May 8, 2026
← Back to all articles
Generated by Yeal